# KEYNOTE-001 (NCT01295827)

> Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01295827
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Cancer, Solid Tumor
- Interventions: Pembrolizumab
- Enrollment: 1260
- Primary outcome: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1)
- Primary outcome: Number of Participants Who Experienced an Adverse Event (AE)
- Primary outcome: Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D)
- Primary outcome: ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F)

## Commentary we found

- YouTube: 6
- Podcasts: 5
- X threads: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-001-nct01295827

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01295827", "email": "<work email>"}; the inbox owner confirms by the emailed link.